These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 20880124)

  • 21. Predictive gene testing for Huntington disease and other neurodegenerative disorders.
    Wedderburn S; Panegyres PK; Andrew S; Goldblatt J; Liebeck T; McGrath F; Wiltshire M; Pestell C; Lee J; Beilby J
    Intern Med J; 2013 Dec; 43(12):1272-9. PubMed ID: 23654213
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patterns of meiotic variability of the (CAG)n repeat in the Huntington disease gene.
    Lucotte G; Gérard N; Aouizérate A; Loirat F; Hazout S
    Genet Couns; 1997; 8(2):77-81. PubMed ID: 9219003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new mutation for Huntington disease following maternal transmission of an intermediate allele.
    Semaka A; Kay C; Belfroid RD; Bijlsma EK; Losekoot M; van Langen IM; van Maarle MC; Oosterloo M; Hayden MR; van Belzen MJ
    Eur J Med Genet; 2015 Jan; 58(1):28-30. PubMed ID: 25464109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The clinical and genetic features of Huntington disease.
    Sturrock A; Leavitt BR
    J Geriatr Psychiatry Neurol; 2010 Dec; 23(4):243-59. PubMed ID: 20923757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regional cortical thinning in preclinical Huntington disease and its relationship to cognition.
    Rosas HD; Hevelone ND; Zaleta AK; Greve DN; Salat DH; Fischl B
    Neurology; 2005 Sep; 65(5):745-7. PubMed ID: 16157910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Triplet repeat mutation length gains correlate with cell-type specific vulnerability in Huntington disease brain.
    Shelbourne PF; Keller-McGandy C; Bi WL; Yoon SR; Dubeau L; Veitch NJ; Vonsattel JP; Wexler NS; ; Arnheim N; Augood SJ
    Hum Mol Genet; 2007 May; 16(10):1133-42. PubMed ID: 17409200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Huntington's disease - clinical signs, symptoms, presymptomatic diagnosis, and diagnosis.
    Shannon KM
    Handb Clin Neurol; 2011; 100():3-13. PubMed ID: 21496568
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Are cognitive changes progressive in prediagnostic HD?
    Stout JC; Weaver M; Solomon AC; Queller S; Hui S; Johnson SA; Gray J; Beristain X; Wojcieszek J; Foroud T
    Cogn Behav Neurol; 2007 Dec; 20(4):212-8. PubMed ID: 18091069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Null alleles at the Huntington disease locus: implications for diagnostics and CAG repeat instability.
    Williams LC; Hegde MR; Nagappan R; Faull RL; Giles J; Winship I; Snow K; Love DR
    Genet Test; 2000; 4(1):55-60. PubMed ID: 10794362
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Are we all of one mind? Clinicians' and patients' opinions regarding the development of a service protocol for predictive testing for Huntington disease. Canadian Collaborative Study for Predictive Testing for Huntington Disease.
    Copley TT; Wiggins S; Dufrasne S; Bloch M; Adam S; McKellin W; Hayden MR
    Am J Med Genet; 1995 Jul; 58(1):59-69. PubMed ID: 7573158
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Usefulness of molecular testing in Huntington's disease.
    Wang V; Yeh TP; Chen CM; Yan SH; Soong BW
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 Sep; 62(9):586-90. PubMed ID: 10502848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autopsy-proven Huntington's disease with 29 trinucleotide repeats.
    Kenney C; Powell S; Jankovic J
    Mov Disord; 2007 Jan; 22(1):127-30. PubMed ID: 17115386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prenatal diagnosis of Huntington disease in maternal plasma: direct and indirect study.
    Bustamante-Aragones A; Trujillo-Tiebas MJ; Gallego-Merlo J; Rodriguez de Alba M; Gonzalez-Gonzalez C; Cantalapiedra D; Ayuso C; Ramos C
    Eur J Neurol; 2008 Dec; 15(12):1338-44. PubMed ID: 19049551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in striatal dopamine D2 receptor binding in pre-clinical Huntington's disease.
    van Oostrom JC; Dekker M; Willemsen AT; de Jong BM; Roos RA; Leenders KL
    Eur J Neurol; 2009 Feb; 16(2):226-31. PubMed ID: 19138335
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Juvenile Huntington's disease: does a dosage-effect pathogenic mechanism differ from the classical adult disease?
    Squitieri F; Frati L; Ciarmiello A; Lastoria S; Quarrell O
    Mech Ageing Dev; 2006 Feb; 127(2):208-12. PubMed ID: 16274727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The neurology and natural history of patients with indeterminate CAG repeat length mutations of the Huntington disease gene.
    Panegyres PK; Goh JG
    J Neurol Sci; 2011 Feb; 301(1-2):14-20. PubMed ID: 21147489
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epidemiology of Huntington's disease in Finland.
    Sipilä JO; Hietala M; Siitonen A; Päivärinta M; Majamaa K
    Parkinsonism Relat Disord; 2015 Jan; 21(1):46-9. PubMed ID: 25466405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of single-nucleotide polymorphisms (SNPs) in OGG1 and XPC on the age at onset of Huntington disease.
    Berger F; Vaslin L; Belin L; Asselain B; Forlani S; Humbert S; Durr A; Hall J
    Mutat Res; 2013 Aug; 755(2):115-9. PubMed ID: 23830927
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Huntington chorea: genetics and biochemistry, diagnosis and therapy].
    Borbás T; Hegyesi H
    Acta Pharm Hung; 2002; 72(2):127-36. PubMed ID: 12498040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low utilization of prenatal and pre-implantation genetic diagnosis in Huntington disease - risk discounting in preventive genetics.
    Schulman JD; Stern HJ
    Clin Genet; 2015 Sep; 88(3):220-3. PubMed ID: 25307798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.